(Q40448944)

English

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.

scientific article published on July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

phase I clinical trial

0 references

author name string

A B Tullo

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

B Esmaeli

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

P I Murray

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

E Bristow

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

B J Forsythe

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

K Faulkner

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

1 reference

based on heuristic

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

729-738

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.eye.6701630

0 references

Ocular toxicity and cancer chemotherapy. A review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

21 January 2018

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of epidermal growth factor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility and differentiation of human corneal epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth factors and corneal endothelial cells: III. Stimulation of adult human corneal endothelial cell mitosis in vitro by defined mitogenic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased expression of the type 1 growth factor receptor family in the conjunctival epithelium of patients with keratoconjunctivitis sicca

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701630

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.EYE.6701630

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40448944&oldid=1749494831"